joint with Transcriptional Regulation
Organizer(s): Sharon Y.R. Dent, Jean-Pierre Issa and Peter A. JonesDate: February 04 - 09, 2014
Location: Santa Fe Community Convention Center, Santa Fe, NM, USA
Epigenetic changes are now recognized to be as important to cancer formation as are gene mutations. Unlike mutations, however, epigenetic states can be altered, and epigenetic therapies hold promise as anti-cancer agents. For these approaches to succeed, we must understand how epigenetic states are created and maintained, and how they are altered in particular malignancies. This meeting will highlight large scale epigenome mapping efforts in normal cells, stem cells, and cancer cells, as well as genetic and biochemical studies focused on defining the mechanistic underpinning of these states. The meeting will bring together basic scientists studying the enzymes that govern epigenetic marks, particularly DNA methylation and histone post translational modifications, with translational and clinical researchers who are developing and implementing new epigenetic therapies. Opportunities for cross fertilization of ideas and interdisciplinary interactions will be further strengthened by joint keynote and plenary sessions with the concurrent meeting on Transcriptional Regulation.
Scholarship Deadline: October 15 2013
Discounted Abstract Deadline: October 15 2013
Abstract Deadline: November 7 2013
Discounted Registration Deadline: December 4 2013
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA181881-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.